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Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH)
represent the three major hepatic autoimmune conditions. Patient morbidity and mortality remain high
across these three diseases, and an unmet need for rational therapy exists. Disease understanding has
focused on combining clinical and laboratory based science to provide better insights into the joint host
and environmental factors necessary for the initiation, and perpetuation, of hepato-biliary inﬂammation.
Twin studies, family studies, population studies and an inter-relationship with other autoimmune
phenomena suggest a genetic component to risk for each disease. Until recently, understanding of this
genetic risk has been limited to HLA haplotypes. Associations with risk-conferring and protective HLA
haplotypes are present in all three diseases. Over the last few years, genome-wide association studies
(GWAS), and related genetic association studies, have greatly increased understanding of the genetic risk
signature of these three diseases and autoimmunity in general. Here we consider the rationale for GWAS
in general and with speciﬁc reference to hepatic autoimmunity. We consider the process of GWAS, and
highlight major ﬁndings to date. Potential functional implications of key ﬁndings are discussed including
the IL-12/STAT4 pathway in PBC and the CD28/IL-2 pathway in PSC. We describe the marked pleiotropy
demonstrated by PBC and PSC, which is consistent with other autoimmune diseases. Further, we focus on
speciﬁc gene associations including SH2B3, which is common to all three diseases, and FUT2 in PSC,
which represents a link between environment and genetics. We review attempts to translate GWAS
ﬁndings into basic laboratory models including in vivo systems and highlight where clinical observations
relate to genetics. Finally we describe deﬁciencies in GWAS to date and consider future study of genetics
in hepatic autoimmunity.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Autoimmunity may be considered as a “clinical syndrome
caused by the activation of T cells or B cells, or both, in the absence
of an ongoing infection or other discernible cause” [1] and is typi-
cally associated with autoantibodies reactive against self antigens
[2]. The prevalence of autoimmunity in general is approaching 10%
[3], and many of these individuals develop autoimmune phenom-
ena affecting multiple organ systems simultaneously [4].
Hepatic autoimmunity comprises three major e and sometimes
overlapping e clinico-pathological syndromes: primary biliary
cirrhosis (PBC; also referred to as primary biliary cholangitis),
autoimmune hepatitis (AIH) and primary sclerosing cholangitis
(PSC) [5e7]. Each is associated with autoantibodies and with an
increased likelihood of autoimmunity affecting other organ sys-
tems. Notably, these are uncommon conditions with the prevalence
of PBC quoted as 1.91e40.2 per 100,000 and PSC as 0e16.2 per
100,000 [8]. Data for AIH aremore sparse, but a recent Danish study
has quoted a prevalence of 23.9 per 100,000 [9]. These diseases can
impact people of all ages, persist as chronic illnesses rather than
acute illnesses, and remain challenging to treat. Of the three dis-
eases, only AIH typically responds to immunosuppression. AIHmay
be separated into type 1 and type 2 with the former more
responsive to immunosuppression. There are few data on the ge-
netics of type 2 AIH and the remainder of this article discusses type
1 AIH.
In each of the three major hepatic autoimmune conditions, as in
most major autoimmune diseases, there is evidence for a strong
genetic component to risk [10]. Genome wide association studies
(GWAS), and related high-density genotyping arrays, represent a
powerful method for exploring the genetic makeup of this risk. This
review for a Special Edition of Journal of Autoimmunity focuses on
the process of applying such studies to hepatic autoimmunity. This
is apt given the life-long contribution from Professors Diego and
Giorgina Vergani in the ﬁeld of hepatology, particularly the pre-
sentation and management, as well as immunologic phenotype, of
autoimmune liver disease in children. The studies discussed herein
parallel and complement such clinical and immunologic evaluation
of these diseases, collectively driving forward our efforts to better
treat patients.
2. Why study genetics in hepatic autoimmunity?
There is a clear genetic component to the risk of developingautoimmunity in general, and hepatic autoimmunity speciﬁcally.
This inference is based on observations made on twin pairs,
family studies, population-based studies, and clinical observa-
tions, and underpins the logic behind conducting GWAS.
Together these observations strongly suggest a signiﬁcant genetic
component to the development of hepatic autoimmunity. A
deeper understanding of genetic associations is hoped to guide
investigation of underlying pathobiology and so translate to
improved therapies, personalized medicine and more accurate
prognostication [11].
2.1. Twin studies
Comparing disease concordance in mono- and dizygotic twins
living in similar environments allows estimation of the relative
contribution from environmental and genetic inputs to disease
risk. Unfortunately, the low frequency of monozygotic twins
(approximately 3.5 per 1000 live births) makes sufﬁcient
recruitment in rarer diseases such as hepatic autoimmunity
challenging.
PBC has the highest reported concordance in monozygotic
twins of any autoimmune condition, with the exception of
celiac disease: 63% in one small series as compared to a risk in
dizygotic twins close to the population level of <0.5% with no
concordance between the 8 pairs studied [12]. Intriguingly, ages
of presentation and presenting symptoms were similar among
concordant twins and two of the discordant twins had other
major autoimmune conditions. Similar data are not currently
available for AIH or PSC, although a in a recent report there was
no genetic concordance in ﬁve dizygotic twin pairs with
concordance in the single set of monozygotic twins from a na-
tional Dutch AIH study [13].
2.2. Familial risk
A particularly increased risk within a family as compared to the
surrounding population tends to suggest an increased genetic risk,
although unrecognized environmental risks are always also
potentially relevant. Such genetic risk can be measured by the
relative sibling risk (denoted as ls) i.e. the increased risk conferred
on the sibling of an individual affected with a certain trait as a
multiple of the baseline population risk. For PBC ls has been
calculated at 10.5 in a large UK series [14] and 10.7 in the USA
[15]. For, PSC ls is approximately10 [16], whilst for AIH estimates
Table 1
Reported coincidence of other autoimmune disease with PBC, PSC and AIH.
Probable or deﬁnite co-incident condition PBC [108] PSC [109] AIH [110]
Sj€ogren syndrome 25 3
Autoimmune thyroid disease 23 4 14a
Rheumatoid arthritis 17 1 28a
Scleroderma 8
Raynaud's phenomenon 24
Systemic lupus erythematosus 1
Autoimmune thrombocytopenic purpura 1
Pernicious anemia 4
Inﬂammatory bowel disease 62% 8
Celiac disease 1 2
Diabetes mellitus 4 9
Psoriasis 3 3
Sarcoidosis 4 1
Proportion with  1 extra-hepatic
autoimmune condition
53% 71% 49%
a The deﬁnitions used when searching for associations with these conditions in
this study were likely to also include non-autoimmune phenomena e.g.
osteoarthritis.
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have a family history of autoimmunity in general [17]. In PBC, the
risk for expressing AMA and for developing disease is increased in
ﬁrst-degree relatives [18,19] and a disproportionate number of PBC
patients have relatives with the disease at the point of diagnosis
[8,20].
2.3. Populations
When one subset of genetically admixed populations in a shared
geographic area have an increased risk of a trait this may also belay
a genetic component to risk. Examples of such phenomena in he-
patic autoimmunity include reports of numbers of individuals
affected by PBC are also abnormally high in ethnically deﬁned sub-
populations [21,22] and within selected wider families in charac-
terized comprehensive healthcare systems [19,23]. Data on PSC
sub-populations are more scarce, and although signiﬁcant variation
is seen between geographically separated populations, this may
also indicate varying environmental exposure [8]. Data in AIH are
similarly lacking with diagnostic variability between countries aFig. 1. The make up of risk for multifactorial autoimmune diseases. The total risk of autoi
risk. Interpreting their relative contributions is made more challenging by those with similar
from geneegene (epistasis) and geneeenvironment interactions. Heritable epigenetic mod
typing techniques.key consideration when drawing comparisons [24].
2.4. Individuals developing multiple autoimmune conditions
suggests shared risk
All three major hepatic autoimmune conditions are strongly
associated with coincident extra-hepatic autoimmunity. The ﬁnd-
ings of three representative reports are summarized in Table 1. Such
observations are consistent with autoimmune conditions in gen-
eral, where development of one autoimmune condition increases
the risk of another. However, this is not always the case and, for
example, a diagnosis of rheumatoid arthritis is protective against a
diagnosis of multiple sclerosis and vice versa [3].
3. The genetic risk proﬁle of hepatic autoimmunity is
challenging to assess
As suggested by the signiﬁcant but relatively modest sibling
relative risk and incomplete concordance in monozygotic twins,
the major hepatic autoimmune conditions do not follow autosomal
inheritance. In contrast, only a small minority of causes of hepatic
autoimmunity are monogenetically inherited: Autoimmune poly-
endocrinopathy candidiasis ectodermal dystrophy [25], heterozy-
gous CTLA4 mutations [26], immunodysregulation polyendocri-
nopathy enteropathy X-linked syndrome [27], and GATA2mutation
[28]may all present with AIH-like syndromes. Notably, all of these
are associated with disruption of the regulatory CD4þ T cell
pathway.
In addition, there is strong evidence of environmental in-
ﬂuences on PBC [15], PSC [29] and AIH [17]. Similarly to their ge-
netic proﬁle, no currently identiﬁed environmental risk factor is
sufﬁcient to explain a large proportion of disease risk. This com-
bination of an uncertain relative contribution to disease risk from
multiple genetic and environmental variables e as well as probable
interactions between these factors e marks these conditions as
multifactorial, polygenetic and complex (Fig. 1) [30].
Unraveling the genetic contribution to disease risk is therefore a
challenge. Prior to GWAS, a large number of candidate gene studies
had been undertaken in hepatic autoimmune diseases [31e33].
However, these studies suffered from relatively weak statisticalmmune diseases is made up of uncertain contributions from environmental and genetic
genetics frequently being exposed to similar environments. There is also a contribution
iﬁcations provide a further potential inﬂuence and may be missed by standard geno-
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reproducibility and were criticized for their a priori approach based
on an incomplete understanding of disease biology. Of the non-HLA
candidate gene associations listed in the three pre-GWAS reviews
cited above, none has subsequently shown signiﬁcant association
in subsequent GWAS.
4. The rationale behind GWAS
GWAS offers an approach that presupposes that there is a ge-
netic component to the risk of developing a disease trait, but seeks
evidence of association across the whole genome without
assuming other prior knowledge. GWAS exploits the common ge-
netic variability that exists between individuals. When considering
a particular trait, GWAS works on the assumption that the risk of
developing the trait of interest is at least partly derived from the
cumulative effect of multiple variants, each of which confers low
risk by itself. If two groups with and without a trait of interest are
compared, certain variants may be disproportionately represented.
If these associations are sufﬁciently speciﬁc and sufﬁciently diver-
gent from the distribution seen in a control group drawn from the
same population, risk may be associated. Further analysis of iden-
tiﬁed risk loci can aid prediction of speciﬁc implicated genes. This
hypothesis-free approach avoids much of the criticism leveled at
candidate gene studies.
GWAS has been made possible by leveraging advances in chip-
based genotyping technology and incremental decreases in the
cost of such techniques [34]. By generating data that are amenable
to combination, the power e and number of associations identiﬁedTable 2
Genome-wide analyses in autoimmune liver disease.
Study Year Patients Controls Replication
cohort Pat/conta
Popu
PBC
Hirschﬁeld et al. [111] 2009 536 1536 526/1206 Whit
Hirschﬁeld et al. [112] 2010 494 1502 857/3198 Whit
Liu et al. [113] 2010 453 945 None Italia
N Am
Mells et al. [114] 2011 1840 5163 620/2514 N Eu
Nakamura et al. [39] 2012 487 476 787/615 Japan
Cordell [98] 2015 2745 9802 3616/4261 N Eu
N Am
PSC
Karlsen et al. [116] 2010 285 298 766/2935 Scan
Melum et al. [117] 2011 715 2962 1025/2174 Scan
Folseraas et al. [118] 2012 715 2962 1221/3508 Scan
Germ
Scan
Cent
and
Srivastava et al. [119] 2012 992 5162 N/A UK C
Ellinghaus et al. [120] 2013 392 2977 1012/2694 Germ
Liu et al. [97] 2013 3789 25079 Pan-
Type 1 AIH
de Boer et al. [36] 2014 649 15,638 466/4103 Dutc
Germ
(repl
Only loci associated at p < 5  108 are included with the exception of SH2B3 (p ¼ 7.7
a Total of all replication cohorts when several used. Where is not yet possible to distine of individual GWAS may be increased by meta-analysis. This also
permits combination of datasets to improve statistical power and
facilitate replication analyses, especially where the same geno-
typing platforms or an overlapping selection of SNVs are used.
Considering ﬁxed genetic information inherently focuses on the
root rather than result of disease process. Potential gains from
GWAS include improvements in predicting whether an individual
will develop a disease, earlier prediction of disease severity or sub-
phenotype, potential biomarker identiﬁcation and improved di-
agnostics. Identifying speciﬁc genes and therefore protein targets
guides the generation of pre-clinical models, informs the devel-
opment of novel candidate drug treatments and may also reveal
opportunities for drug re-purposing [11,35].
5. The process of GWAS
Conducting GWAS requires the assembly of cohorts of in-
dividuals with and without a trait of interest. Care must be taken to
assess for the presence of over-lapping conditions, which may bias
genetic risk associations and misdiagnoses, which may dilute risk
associations. Relevant examples include the presence or absence of
ulcerative colitis in PSC or in distinguishing Type 1 from Type 2 AIH
[30,36]. Although, ﬁnding sufﬁcient well-phenotyped cases in
these relatively rare diseases can be challenging, over the last
decade high-throughput genetic studies have transformed our
understanding of the risk architecture of autoimmune conditions in
general and hepatic autoimmunity in particular (Table 2).
Once appropriate test and control cohorts have been assembled,
each subject of both groups is genotyped for a wide array oflation Loci implicated Notes
e N American HLA, IL12A, IL12RB2
e N American IRF-TNPO3, MMEL1, IKZF3 Extension of [111]
n and meta
erican
SPIB, IKZF3, IRF5-TNPO3 Combination study
with [111] population
ropean DENND1B, STAT4, CD80,
NFKB1, IL7R,
CXCR5, TNFRSF1A, RAD51L1,
CLEC16A, MAP3K7IP1; PLCL2,
RPS6KA4, TNFAIP2(in
combination
with Italian data [115])
ese HLA, TNFSF15, POU2AF1 Japanese
ropean, Italian,
erican
IL1R1, CCL20, DGKQ,
C5orf30, IL12B, TNFAIP3
Large meta-analysis
dinavian, German HLA
dinavian, German HLA, BCL2L11, MST1
dinavian and
an discovery;
dinavian,
ral European
US replication
MMEL1-TNFRSF14 Fine-mapping
study based on [117]
aucasians MST1, IL2RA Replication study
an, Scandinavian GPR35, TCF4 Combined analysis
with ulcerative cases
European, N America HLA, MMEL1-TNFRSF14, CD28,
MST1, IL2/IL21, BACH2, IL2RA,
SIK2, HDAC7, SH2B3,
CD226, FUT2, PSMG1
h (discovery);
an/Swiss
ication)
HLA, SH2B3
 108).
guish between several candidate genes, a single example has been given.
Table 3
HLA associations of hepatic autoimmune diseases.
PBC
Risk conferring
HLA-DQA1*04:01-DQB1*04:02-
DRB1*08:01-B*39:05
[58,96]
N. Am, UK, Ital
*
HLA-DRB1*04:04-DQB1*03:02 [58,96]
N. Am, UK, Ital
*
HLA-DRB1*14-DPB1*03:01 [42]
Ital
*
HLA-DRB1*08:03-DQB1*06:01 [64,69] Jap, Chin
HLA-DRB1*04:05-DQB1*04:01 [69] Jap
Protective
HLA-DQB1*06:02-DRB1*15:01-
DQA1*01:02-B*07:02
[58,96]
N. Am, UK, Ital
*
HLA-DQB1*03:01-DRB1*11:01-
DQA1*05:01-DRB1*11:04
[58,64,96]
N. Am, UK, Ital, Chin
*
HLA-DRB1*13:02-DQB1*06:04 Jap [69]
HLA-DRB1*11:01-DQB1*03:01 Jap [69]
PSC
Risk conferring
HLA-B*08:01 [86], N. Am inc Afr-Am
HLA-DRB1*03:01-DQA1*05:01-
DQB1*02:01
[121]N. Am, N. Euro
HLA-DRB1*13:01-DQA1*01:03-
DQB1*06:03
HLA-DRB1*15:01-DQA1*01:02-
DQB1*06:02
HLA-DRB1*01:01-DQA1*01:01
Protective
HLA-DRB4*01:03-DRB1*04:01-
DQA1*03-DQB1*03:02
HLA-DRB4*01:03-DRB1*07:01-
DQA1*02:01-DQB1*03:03
HLA-DRB4*02:02-DRB1*11:01-
DQA1*05:01-DQB1*03:01
[122]
AIH (Type 1)
Risk conferring
HLA-A1-HLA-B8-DRB3*01:01-DRB1*03:
01-DQA1*05:01-DQBl*02:01
N Euro [123]
HLA-DR4*04:04 and HLA-DRB*04:05 Jap [124], Cent Am, China
HLA-DRB1*04:01 N Euro
DRB1*13:01-DQB1*06 Lat Am [125]
HLA-DRB1*01 and HLA-DRB1*14 W. India [126]
Protective
HLA-DRB5*01:01-DRB1*15:01 N Euro [123]
HLA-DQB1*04-DQB1*03:01 Lat. Am. [125]
[126]* Dense SNV analysis and subsequent conditional analysis of this HLA haplo-
type in the Italian PBC cohort has suggested that risk-conferring/protective effects
are predominantly due to variants in HLA-DRB1 with associated linkage disequi-
librium [42].
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selected from those sufﬁciently prevalent in the general popula-
tion, and sufﬁciently spaced across the genome, to power subse-
quent statistical association analysis. SNV selections are drawn
from large haplotype mapping projects, particularly the Interna-
tional HapMap project. In the case of GWAS, these traits are chosen
from variations identiﬁed during sequencing efforts to dissect the
genome and are spread across it. Inmore focused studies, a targeted
selection of SNVsmay be used. In the case of the Immunochip, SNVs
implicated in immune pathways and other autoimmune diseases e
including some rarer than those used in most GWASeare used to
allow ﬁner-resolution analysis of loci of interest [37].
The analysis of large-scale GWAS-derived datasets enables
identiﬁcation of individual variants with estimates of the risk that
they confer. Notably, far more common SNVs have been described
than have been assessed in any one GWAS. Therefore over-
representation of a given SNV in one cohort or another is likely to
represent linkage disequilibrium rather than the causative muta-
tion itself. Exploitation of linkage disequilibrium e the phenome-
non by which genes located closer together on are more frequently
inherited together e allows likely risk loci to be identiﬁed and
therefore candidate genes within or near such loci inferred [38].
Thus, GWAS does not typically detect speciﬁc mutations and the
resolution of a particular studymaymake it difﬁcult to comment on
the speciﬁc gene implicated. Several GWAS ‘hits’ in hepatic auto-
immunity may still relate to one of several proposed genes.
The multiple comparisons made in GWAS make both statistical
correction and the use of a conservative level of statistical signiﬁ-
cance mandatory. Typically, overall values of p < 5  108 are taken
as indicating signiﬁcance in a genome-wide study. A key potential
confounder in GWAS is the potential for false positives/type 1 errors
because of the multiple comparisons inherent to its analysis. Thus,
careful adjustment for the number of such comparisons is
mandatory. Also mandatory is conﬁrmation of associations by
replication in separate validation cohorts.
An important component of GWAS is comparing the test cohort
with a suitable control: i.e. one that would be expected to have a
similar distribution of common SNVs other than those associated
with the disease trait of interest. Typically this means a control
cohort drawn from healthy individuals in an ethnically and
geographically similar area. With the notable exception of the
Japanese PBC GWAS [39], all of the studies performed in hepatic
GWAS to date have concentrated on populations of predominantly
white European origin. Two associations from the Japanese PBC
cohort (POU2AF1 and TNFSF15) are unique to that study. Also, recent
work in a Chinese cohort failed to replicate an association in the IL-
12 pathway that has proven reproducible in European populations
[40].
Following the broad model described above, risk loci associated
with PBC, PSC and AIH at genome-wide signiﬁcance levels
(p < 5  108) have been identiﬁed and these are summarized in
Tables 3 and 4. This number will increase with larger, and higher
resolution, studies e.g. there is an ongoing effort to perform ameta-
analysis of PSC GWAS datasets. Notably, there is a high degree of
overlap (or pleiotropy) between loci implicated in hepatic auto-
immunity to date and those associated with other autoimmune
conditions (Fig. 2).
6. Major observations in hepatic autoimmunity resulting
from GWAS
6.1. HLA associations
GWAS has given robust support to a number of associations with
HLA haplotypes with each of the major diseases. Several of theseassociations were made prior to the GWAS era. HLA associations
strongly implicate the adaptive immune system: the HLA region on
chromosome 6is highly variable encodes both the class I and II
major histocompatibility complexes. Associations are summarized
in Table 3. All three hepatic autoimmune diseases have associations
with variants in both class I (encoded by HLA-A, HLA-B and HLA-C)
and class II (HLA-D)major histocompatibility complexes, withmore
associations in HLA-D. HLA haplotype associations are seen in all
major autoimmune diseases (Fig. 2).
SNVs affecting HLA can alter the MHC antigen presentation
repertoire and have been associated with disease provoking re-
sponses in response to otherwise innocuous certain agents: for
example HLA-B*57:01 and abacavir hypersensitivity [41]. In PBC
much of the risk has been narrowed to HLA-DRB1 with much of
these rest of the association signal attributed to linkage disequi-
librium [42].
One theory that complements speciﬁc HLA associations with
speciﬁc diseases alongside multiple shared other non-HLA variants
is that HLA haplotypes may direct autoimmunity in an otherwise
prone individual, perhaps after an environmental trigger. For
Table 4
Major non-HLA associations from GWAS in hepatic autoimmunity.
Locus PBC PSC AIH Study SNV OR P-value Candidate gene(s) Selected functional notes
1p36 x [112] rs3748816 1.33 3.15E-08 MMEL1
1p36 x [97] rs3748816 1.21 7.41E-12 MMEL1, TNFSFR14
1q31 x [114] rs12134279 1.34 2.06E-14 DENND1B
2q12 x [98] rs12712133 1.14 5.19E-09 IL1RL1, IL1RL2, Also known as ST2. Antigen-presenting cell receptor for IL-33. Promotes
type 2 immune responses [127]
2q13 x [117] rs6720394 1.6 4.10E-08 BCL2L11 Also known as BIM; may promote apoptosis and inhibit autophagy
[128]
2q32 x [114] rs10931468 1.5 2.35E-19 STAT4, STAT1 See Fig. 4
2q33 x [97] rs7426056 1.3 1.89E-20 CD28 Receptor that supplies co-stimulatory signals to T cells; See Fig. 3 [129]
2q36 x [98] rs4973341 1.22 2.34E-10 CCL20 Chemo-attractant to lymphocytes and neutrophils; strongly expressed
in the liver [130]
2q37 x [120] rs4676410 1.38 2.43E-09 GPR35 Also known as CXCR8. Receptor for CXCL17 involved in mucosal
leucocyte recruitment, including monocytes-macrophages [131]
3p21 x [97] rs3197999 1.33 2.45E-26 MST1 Involved in TNF induced cell death, apoptosis, tumor suppressing in
liver [132]
3p24 x [114] rs1372072 1.2 2.28E-08 PLCL2 Transcription factor involved in B cell proliferation
3q13 x [96] rs2293370 1.39 6.84E-16 CD80 Co-stimulatory molecule e which together with CD86 e is important
for T cell activation via CD28 [129]
3q25 x [96] rs2366643 1.35 3.92E-22 IL12A See Fig. 4
4p16 x [98] rs11724804 1.22 9.01E-12 DGKQ
4q24 x [114] rs7665090 1.26 8.48E-14 NFKB1 The transcription factor NFkB plays important roles in both the innate
and adaptive immune system [133,134], inﬂuencing both B and T cell
activation downstream of the antigen receptors and promoting
inﬂammatory responses
4q27 x [97] rs13140464 1.3 8.87E-13 IL2, IL21 IL2: see ﬁgure
5p13 x [96] rs6871748 1.3 2.26E-13 IL7R Important in lymphocyte development; loss of function mutations
result in lymphopaenia and an autoimmune pre-disposition (product
also known as CD127)
5q21 x [98] rs526231 1.15 1.14E-08 C5orf30
5q33 x [98] rs2546890 1.15 1.06E-10 IL12B, LOC285626 See Fig. 4
6q15 x [97] rs56258221 1.23 8.36E-12 BACH2 Regulatory protein with effects on apoptosis and key to antibody class
switching [135]; represses effector lines of CD4þ T cells [136]
6q23 x [98] rs6933404 1.18 1.27E-10 OLIG3, TNFAIP3 TNFAIP3: zinc ﬁnger protein which modulates NFkB and STAT
pathways, and TNF receptors signaling [137]
7p14 x [114] rs6974491 1.25 4.44E-08 ELMO1
7q32 x [96] rs35188261 1.52 6.52E-22 IRF5 Transcription factor mediating effects of TLR ligation
9p32 x [39] rs4979462 1.57 1.85E-14 TNFSF15
10p15 x [97] rs4147359 1.24 8.19E-17 IL2RA Product also known as CD25. See Fig. 3
11q23 x [39] rs4938534 1.38 3.27E-08 POU2AF1 AKA Oct binding factor 1 (OBF1).A transcription factor involved in B cell
development [138].
11q13 x [114] rs538147 1.23 2.06E-10 RPS6KA4
11q23 x [97] rs7937682 1.17 3.17E-09 SIK2 Modulation of inﬂammatory cytokine production by murine
macrophages [139]
11q23 x [96] rs80065107 1.39 7.20E-16 CXCR5, DDX6 CXCR5: Major role in B cell and T follicular helper cell trafﬁcking to
germinal centres.
12p13 x [96] rs1800693 1.27 1.18E-14 TNFRSF1A, LTBR TNFRSF1A encodes a member of the tumor necrosis factor family of
receptors. It is predominantly expressed on antigen-presenting cells
and represents a major receptor for tumor necrosis factor alpha (TNFa).
Activation of this receptor can cause apoptosis through activation of
NFkB and mutations leading to its constitutive activation are associated
with periodic fever syndrome [140].
12q13 x [97] rs11168249 1.15 5.49E-09 HDAC7 Histone deacetylase implicated in the suppression of myeloid lineage
genes in lymphoid cells [141]
12q24 x [97] rs3184504 1.18 5.91E-11 SH2B3, ATXN2 SH2B3: Also known as 'Lnk'. Adaptor protein involved in multiple cell
surface signaling pathways in both hematopoietic and non
hematopoietic cells. Mutations are implicated in myeloproliferative
conditions including malignancies [142].
12q24 x [96] rs11065979 1.2 2.87E-09 SH2B3
12q24 x [36] rs3184504 1.4 7.70E-08 SH2B3*
13q14 x [96] rs3862738 1.33 2.18E-08 TNFSF11 AKA RANK-ligand or TNF-related activation-induced cytokine
(TRANCE). TNFR ligand involved in control of osteoclast activity, and
dendritic cell survival factor. Deﬁciency results in impaired lymphocyte
differentiation [143].
14q24 x [96] rs911263 1.26 9.95E-11 RAD51B
16p13 x [96] rs12708715 1.29 2.19E-13 CLEC16A, SOCS1 SOCS1: has a regulatory effect on both NFkB and JAK-STAT pathways
including STAT4 [134]
16q24 x [114] rs11117432 1.31 4.66E-11 IRF8 Transcription factor mediating effects of TLR ligation.
14q32 x [114] rs8017161 1.22 2.61E-13 TNFAIP2
17q12 x [96] rs17564829 1.26 6.05E-14 IKZF3 hematopoietic transcription factors and is involved in lymphocyte
development and proliferation, especially in B cells. Dysfunction causes
generalized autoimmunity [144]
17q21 x [96] rs17564829 1.25 2.15E-09 MAPT
18q21 x [120] rs1452787 1.33 2.61E-08 TCF4 Transcription factor implicated in lymphoid development and epithelial
emesenchymal transition [145]
18q22 x [97] rs1788097 1.15 3.06E-08 CD226 Adhesion molecule expressed on NK cells, T cells, platelets and
monocytes; modulator of NK cytotoxicity [146]
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Table 4 (continued )
Locus PBC PSC AIH Study SNV OR P-value Candidate gene(s) Selected functional notes
19p12 x [96] rs34536443 1.91 1.23E-12 TYK2 Signaling kinase in IL-12 and IL-23 receptor signaling. In systemic lupus
erythematosus variants to inﬂuence IFNg production [147].
1p31 x [96] rs72678531 1.61 2.47E-38 IL12RB2 See Fig. 4
19q13 x [97] rs60652743 1.25 6.51E-10 FUT2, PRKD2, STRN4 FUT2: Antigen expression e see main text
19q13 x [115] rs3745516 1.46 7.97E-11 SPIB Transcription factor mediating B cell receptor signaling
21q22 x [97] rs2836883 1.28 3.19E-17 PSMG1 Embryonically lethal if functionally absent in mice; deﬁcient
hepatocytes demonstrated premature senescence [148]
22q13 x [96] rs2267407 1.29 1.29E-13 SYNGR1
Lowest p value shown where different studies have implicated the same variant. All candidate genes identiﬁed here have association signals with p < 5  108 with the
exception of the SH2B3 signal in AIH (see text). Not all candidate genes represented for some loci.
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velops insulitis and diabetes, but altering its HLA alleles can redirect
the autoimmune focus to thyroiditis [43]. Of note however, the
haplotypes associated with each of the hepatic autoimmune dis-
eases are variable between geographic and ethnic populations
(Table 3). It remains unclear as to whether the overlapping gene
variants contained within these haplotypes of the highly variable
HLA region represent true divergent developments resulting in a
risk for a similar phenotype, or whether the risk will in due course
be narrowed down to very few SNVs as it has in rheumatoid
arthritis [44].
6.2. Non-HLA associations
Multiple non-HLA associations have now been identiﬁed in both
PBC and PSC by GWAS. These are summarized with brief notes as to
the function of better-understood implicated genes in Table 4.
Below, we consider associations forming patterns within pathways
and of associations with genes of particular interest. Notably bio-
logical studies are needed to complete the understanding of pro-
posed gene associations.
6.2.1. The IL-2 pathway in PSC
The combination of loci associated with PSC risk containing
CD28, IL2 and IL2RA ewhich encodes the alpha subunit of the high
afﬁnity IL-2 receptor e suggest that the T lymphocyte focused IL-2
pathway has a major role. The multiple effects of IL-2 are sum-
marized as Fig. 3 and the molecule has key roles in the develop-
ment and maintenance of regulatory T cells but is also important in
the adaptive effector response.
The IL2RA deﬁcient mouse develops marked lymphadenopathy
with ultimately fatal autoimmunity with lymphocytic inﬁltrates in
skin, intestine, lung and liver in the context of a complete deﬁ-
ciency of regulatory T cells. The liver inﬁltrate is peri-portal but
occurs without overt ﬁbrosis and, owing to its development of anti-
mitochondrial antibodies, the mouse has in fact been described as a
model of PBC [45]. Indeed, a single case of a boy with a homozygous
mutation in IL2RA developing a PBC-like disorder with Treg deﬁ-
ciency has been described [46]. By analogy to IL2RAmutations, mice
deﬁcient in the leucocyte anti-apoptotic protein Bcl2l11 also
develop multi-system autoimmunity with lymphocytic inﬁltration
and autoantibodies, but without a hepatic focus in a pattern that
has been described asmore like systemic lupus erythematosus [47].
6.2.2. The IL12-STAT4 pathway in PBC
PBC risk has been attributed to variants in a number of genes
involved in the T cell activation pathway involving IL-12 and STAT4,
which leads to Th1 T cell polarization (Fig. 4). IL-12 is a hetero-
dimeric molecule made up of the two subunits, p35 and p40,
encoded by the IL12A and IL12B genes respectively. The latterprotein also heterodimerizes with IL-23p19 to form IL-23, a key
signaling component in the Th-17 pathway. The IL-12 receptor is
also encoded by two genes: IL12RB1, which is constitutively
expressed, and IL12RB2which is upregulated by interferon-g (IFNg)
to act as a positive feedback loop in antigenic stimulation. STAT4
and tyrosine kinase 2 (TYK2) protein are important in both IL-12
and IL-23 receptor signaling. Each of IL12A, IL12RB2, STAT4 and
TYK2 have risk associations with PBC. Deﬁciencies in IL12 and
STAT4 confer susceptibility to intracellular pathogens such as
tuberculosis [48,49], whilst STAT4 is required for developing
autoimmune diabetes in a mouse model [50].
Using animal models of PBC, efforts have been made to see
whether interruption of the IL-12 pathway ameliorates autoim-
mune liver disease. Results have been variable and all depended on
models of PBC created by introducing profound defects in T cell
regulatory pathways: deletion of the IL-12p40 subunit worsens
peri-biliary inﬂammation and upregulates hepatic expression of
gene products associated with ﬁbrosis in IL2Ra deﬁcient mice [51];
in dnTGFbRII mice, IL-12p40 deletion greatly reduced peri-biliary
inﬂammation [52]; whereas IL-12p35 delayed but did not prevent
disease in dnTGFbRII mice and was also associated with more
marked ﬁbrosis [53].6.2.3. FUT2
The linkage of the gene FUT2 to PSC risk is of interest because it
resonates with two other major potential etiological considerations
in the disease: the gut microbiome and antigen presentation. FUT2
encodes fucosyl transferase 2 and is involved in the regulation of
the expression of antigens including the ABO system and in the
synthesis of the H antigen oligosaccharide. The latter acts a binding
moiety for a number of bacteria and viruses including the Norwalk
virus and also a source of carbon for certain bacteria. In those ho-
mozygous for the disease-associated SNV demonstrate alterations
in gutmicrobial community composition [54], FUT2 variants appear
to affect carbohydrate metabolism in the gut, so affecting the
microbiome. Such alterations, and FUT2 variations, have been
associated with sub-clinical colitis in both mice and man [55]. FUT2
variants are also recognized as conferring risk in inﬂammatory
bowel disease.6.2.4. SH2B3 e Lnk
SH2B3 e also known as Lnk e is notable for being associated
with all three of the hepatic autoimmune diseases. The association
signal in the single AIH GWAS to date falls slightly short of the
generally-accepted level for genome-wide signiﬁcance, but it has
been argued that the high likelihood of SH2B3's involvement given
its role in so many other autoimmune diseases means that it should
be considered a signiﬁcant association. SH2B3 encodes one a
number of SH2B adaptor proteins and is within a widely shared
autoimmune locus. It is involved in multiple growth factor and
Fig. 2. Many genetic associations of PBC, PSC and AIH are shared with other autoimmune diseases. Circos plot [101] of gene variants associated with PBC, PSC and AIH alongside
other autoimmune conditions in high-throughput genetics studies and their meta-analyses. Note that signiﬁcant pleiotropy exists with some loci implicated in multiple conditions
and variable HLA associations a universal feature. PBC ¼ primary biliary cirrhosis; PSC ¼ primary sclerosing cholangitis; AIH ¼ autoimmune hepatitis; AA ¼ alopecia areata;
AS ¼ ankylosing spondylitis; ATD ¼ autoimmune thyroid disease; JIA ¼ juvenile idiopathic arthritis; MG ¼ myasthenia gravis; MS ¼ multiple sclerosis; Narc ¼ narcolepsy;
Pso ¼ psoriasis; RA ¼ rheumatoid arthritis; Scl ¼ scleroderma; Sj€o ¼ Sj€ogren's syndrome; SLE ¼ systemic lupus erythematosus; T1DM ¼ type 1 diabetes mellitus; UC ¼ ulcerative
colitis; Vit ¼ vitiligo. Only validated associations at p < 5  108 are included (with the exception of SH2B3 in AIH e see text); supporting citations are available at request.
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activation, tumor necrosis factor and Janus kinase 2 and 3 (JAK2/3)
signaling and is required for normal hematopoiesis. Mice deﬁcient
in SH2B3 have greater levels of activated T cells and a tendency to
autoimmunity [56].
SH2B3 variants are also implicated in celiac disease. Investiga-
tion of the functional effect of SH2B3 genotype in response to
lipopolysaccharide and muramyl dipeptide has demonstrated that
the risk that carriers of the SH2B3 rs3184504*A risk allele e which
is the same as that implicated in PSC and AIH e show stronger
activation of the NOD2 pathogen recognition pathway [57]. This
suggests that SH2B3 has a role in modulating the immune responseto intestinal pathogens.
6.2.5. Epistasis
Epistasis is the process by which carrying a combination of two
or more risk variants has a more than additive effect on total risk.
One example of such interactions in PBC is the risk-conferring
epistatic interaction between the 1p31 (IL12RB2) and 7q32 (IRF5)
loci [58]. A potential risk-amplifying interaction between CTLA4
and TNFa variants has also been reported in the pre-GWAS era, but
not replicated [59]. Numbers of epistatic geneegene interactions
are likely to grow as sample sizes increase and meta-analysis is
carried out.
Fig. 3. Schematic representation of the IL-2 pathway, which is implicated in PSC by GWAS. The combination of TCR and CD28 signals upregulate IL-2 production in activated T
cells, especially CD4þ T cells. T cell activation without co-stimulatory CD28 signal results in anergy with minimal IL-2 production. In general, IL-2 has pro-effector actions. However,
in IL-2 deﬁciency or deﬁciency of IL-2 receptor alpha, there is widespread autoimmunity and lymphoproliferation ascribed to a failure to generate regulatory T cells. In developed
immune systems however, exogenous IL-2 typically ampliﬁes T cell responses. IL-2 receptor complex may exist as a dimer (from IL-2Rb and/or IL-2Rg) or trimer (with IL-2Ra). The
addition of IL-2Ra renders the receptor complex with much higher afﬁnity to IL-2, and is particularly important for regulatory T cells. Cytokines secretion is shown as dashed
arrows; positive effects are shown as solid arrows. Labels in red denote factors implicated by GWAS to date. Abbreviations: APC ¼ antigen-presenting cell; CD ¼ cluster of dif-
ferentiation; IL ¼ interleukin; AICD ¼ activation-induced cell death; IL2R ¼ IL-2 receptor; IFNg ¼ interferon gamma; TNFa ¼ tumor necrosis factor alpha; Treg ¼ regulatory T cell
[102e105]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Translating ﬁndings from GWAS studies in general to changes of
clinical care has proved challenging. Notable exceptions exist
however, for example the utility of IL-12 and IL-23 blockade in
psoriasis [60] and the identiﬁcation of the link between IL28B
variants and sustained virological response in hepatitis C treatment
[61].7.1. HLA
There has been some success in predicting clinical characteris-
tics from GWAS data, but prospective validation is required. For
example, work arising form the Dutch AIH GWAS has suggested
that HLA types inﬂuence clinical characteristics: HLA-DRB1*03:01
being associated with higher serum gamma immunoglobulin
levels and HLA-DRB1*04:01 being associated with an older age of
ﬁrst presentation [62].
A number of pre-GWAS studies have related clinical character-
istics to HLA haplotypes, although many have not been replicated.
The well-established inter-population variability between HLA as-
sociations means that results must be applied between varying
populations with caution. In PBC for example, HLA haplotypes
correlate with anti-gp210 status in Japanese [63] and Chinese [64]
patients. The presence of anti-gp210 antibodies is independently
predictive of outcome. HLA-associated susceptibility to UC is
different with and without the presence of concurrent PSC [65] and
acute rejection after transplantation may also be associated withHLA-B*08, HLA-C*07 and HLA-DRB1*03 [66]. In AIH, HLA-DR4 may
predict treatment failure [67]. Sequencing of DRB1*03-DRB1*04
amongst North American patients has shown a lysine-rich subset in
which carriers with AIH more frequently develop cirrhosis and a
requirement for liver transplantation [68]. Similarly, amongst Jap-
anese with AIH, the DRB1*08:03-DQB1*06:01 haplotype was more
frequent in patients who developed hepatic failure [69].
The mechanism by which given HLA variants may exert their
effects in hepatic autoimmunity is unclear. However, in PBC recent
important work has directly linked HLA-types to cellular pheno-
type. T cells with the risk-conferring HLA-DRB1*08:01 shown a
high-afﬁnity response to speciﬁc pyruvate dehydrogenase E2 sub-
unit peptides; an analogous responsewas absent in cells expressing
the protective HLA-DRB1*11:01 [70].7.2. Non-HLA
The implication of the IL-2 pathway in PSC might logically
suggest a role for immunosuppressants. However, no immuno-
suppressive regime, including those with particular activity against
IL-2 has proven efﬁcacy in PSC [71]. Similarly, despite a number of
molecules implicated in activation of the adaptive immune system
in PBC, no immunosuppressive therapy has been shown effective to
date.
The alpha-subunit of the IL2 receptor complex (IL2RA; CD25) is
also implicated by GWAS in PSC. This had lead to particular interest
in regulatory T cells, which strongly express IL2Ra. Recent work
attempting to address the role of regulatory T cells in PSC has
Fig. 4. Schematic representation of the IL-12 pathway,which is implicated in PBC by GWAS. Antigen activates APC through TLR. APC in turn produce IL-12 after phosphorylation
of IRF5. Antigen is presented to CD4þ T cells by HLA II with co-stimulation via CD80 and 86 to CD28. There is competitive inhibition of this co-stimulation by CTLA4. IL-12 activates a
cascade of signaling factors including NFKB and STAT4 to promote the production of Th1-type cytokines including TNFa and IFNg; the transcription factor IRF8 is involved. IL7R
supports lymphocyte development. There is positive feedback from Th1 cytokines to APCs. Red text denotes conﬁrmed risk associations with PBC. Arrows denote positive effects;
barred lines denote negative effects. APC ¼ antigen-presenting cell; CD ¼ cluster of differentiation; CTLA4 ¼ Cytotoxic T lymphocyte antigen 4; HLA II ¼ human leucocyte antigen
class II; IFN-g ¼ interferon-g; IFNgR ¼ interferon-g receptor; IL-12 ¼ interleukin-12; IL-12Rb1/2 ¼ IL-12 receptor b subunits 1 and 2; IL7R ¼ interleukin-7 receptor; IRF5 and
IRF8 ¼ interferon response factors 5 and 8; JAK2 ¼ Janus kinase 2; Lck ¼ lymphocyte-speciﬁc protein tyrosine kinase; NFKB ¼ nuclear factor kappa-light-chain-enhancer of
activated B cells; PKC ¼ protein kinase C; SOCS1 ¼ suppressor of cytokine signaling 1; STAT4 ¼ signal transducer and activator of transcription 4; TCR ¼ T-cell receptor; TLR ¼ Toll-
like receptor; TNFAIP3 ¼ tumor necrosis factor alpha-induced protein 3; TNFRSF1a ¼ Tumor necrosis factor receptor superfamily 1a; TNFa ¼ tumor necrosis factor alpha;
TYK2 ¼ Tyrosine kinase 2 [106,107].
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with PBC [72]. Further, peripheral populations were reduced and
this correlated with homozygosity for the risk IL2RA allele.
The proportion of liver-inﬁltrating lymphocytes expressing
CD28 in PSC is reduced and these cells have a more activated
phenotype and produce more of the effector cytokines tumor ne-
crosis factor a and interferon-g than their CD28þ counterparts [73].
Interestingly, the CD28-negative T cell compartment is also
expanded in rheumatoid arthritis, in which the CD28 gene is
similarly implicated by GWAS [74].
In follow-up studies of GWAS datasets, associations of STAT4
variations with ANA status have been identiﬁed in Japanese PBCpatients [75] and TNFSF15 polymorphisms have been linked to
functional changes in the gene product. Differences in mRNA and
protein expression were also seen in both PBC and healthy subjects
carrying this variant, although a link to outcome or phenotype re-
mains unclear [76].
The risk association with CXCR5 is of particular interest because
of CXCR5's major role in lymphocyte trafﬁcking, especially of B and
T cells migrating to germinal centers. Subsequent to GWAS, two
observations have strengthened the link to the clinical picture:
ﬁrstly that numbers of CXCR5þ T follicular helper cells are increased
both peripherally and in PBC liver tissue [77,78] and secondly that
the ligand for CXCR5, CXCL13, is upregulated in PBC as compared
G.J. Webb, G.M. Hirschﬁeld / Journal of Autoimmunity 66 (2016) 25e39 35with other liver diseases [79].
A common feature of PBC, PSC and AIH is that they all recur after
transplantation. This supports a key role for the immune system
rather than an intrinsic biliary epithelial cell or hepatocyte defect.
In PBC, data gathered as part of the UK-PBC cohort was re-analyzed
according to individuals' IL12A variant status and this has suggested
a correlation between the AG variant and decreased time to diag-
nosis of PBC recurrence [80].
The IL12 pathway is also the target of the only GWAS-derived
therapeutic intervention to date in hepatic autoimmunity. This
study used ustekinumab, a monoclonal antibody that blocks IL-12
and IL-23 signaling. However, administration to PBC patients with
established cholestatic, ursodeoxycholic-unresponsive disease did
not signiﬁcantly alter biochemical surrogates of disease activity
[81]. However intriguingly in those patients in whom there was a
fall in alkaline phosphatase noted, there was evidence of modula-
tion of biological pathways (including Th17 lymphocytes) related to
ustekinumab response.
Finally, work has been published attempting to calculate risk
using aggregated GWAS data and applying these to cohorts. There
has been some success, with a recent risk score generating a
modest AuRoC of 0.72. This is despite the same authors calculating
a combinatorial disease risk from all extant PBC susceptibility al-
leles of only 5.3% of the observed heritable risk, suggesting the
capacity for future reﬁnement [82].8. Deﬁciencies in GWAS to date
8.1. GWAS results do not account for all the observed risk
One reason for this is that these rare diseases are likely to have
some of their risk conferred by rare genetic variants. The design of
GWAS means that identiﬁed risk variants are, by deﬁnition, more
frequent in the population than is the disease per se [83]. Further,
rarer genes with smaller effect sizes require larger cohorts for as-
sociation signals to reach the stringent levels of statistic signiﬁ-
cance: this effect has been especially apparent in more common
autoimmune diseases. For example, there is an almost direct cor-
relation between study size and the number of variants identiﬁed
in inﬂammatory bowel disease [37] and studies of super-cohorts
involving over 100,000 subjects have greatly clariﬁed the genetic
landscape of rheumatoid arthritis [84].
Importantly, it is apparent that GWAS will never account for all
of the observed risk in complex diseases like those in hepatic
autoimmunity: in PSC it has been commented that “more than 50%
of the susceptibility to these diseases is still likely to be of an
environmental origin.” [85] Equally, in PBC, which has seen the
greatest amount of GWAS investigation, calculation suggests that
ﬁndings to date only account for a few percent of the observed
heritability [82].8.2. Genetic information cannot yet explain key aspects of disease
phenotype
As yet, GWAS does not explain key phenotypic features of the
hepatic autoimmune diseases. Examples of these include the
marked differences in risk between genders, the co-incidence of
other autoimmune phenomena, treatment response in PBC and
AIH, and malignancy risk in PSC. Genetic risk also does not help
explain the evolution of clinical phenotype that is particularly
recognized in pediatric patients presenting with autoimmune
hepatitis and sclerosing cholangitis.8.3. GWAS does not reﬂect disease risk in varied ethnicities
As mentioned above, all major GWAS in hepatic autoimmunity
to date have focused on populations of European Caucasian
descent, with the exception of the Japanese PBC study [39]. The
Japanese GWAS identiﬁed two associations not yet replicated in
other populations. Similarly, a recent replication study from China
in a Han population has suggested incomplete overlap with pre-
vious studies [40]. Observations like the lower rate of concurrent
ulcerative colitis in African American PSC patients suggest genetic
variation may be implicated [86]. The selection of SNVs assessed by
Immunochip are also biased to white Caucasian populations [87]. It
therefore remains possible that associations in those of non-
European backgrounds will yield different associations.
8.4. Positive selection pressure for genes implicated by GWAS is not
yet explained
Several associations uncovered in GWAS have putative links to
resistance to microbial infection: IL-12/STAT4 pathway and intra-
cellular/tubercular infection in PBC; FUT2 and Norwalk virus in PSC;
SH2B3 and response via NOD2 in AIH, PSC and PBC [49,54,57].
However, for the most variants associated with hepatic autoim-
munity no explanation exists for the selection force that explains
their presence in the population. It is likely that responses to mi-
crobial agents will be implicated: most of human variation is
thought attributable to infectious disease [88] and gut pathogens
are thought to have dictated the genetic signature of inﬂammatory
bowel disease [89].
8.5. GWAS does not yet map to animal models nor therapies
As considered above, there is a current lack of either a direct
animal model in which abnormalities in a gene identiﬁed by GWAS
recapitulate the key phenotypic components of one of the major
autoimmune hepatic disease. Equally, no targeted therapy based on
GWAS ﬁndings has yet been successful.
8.6. GWAS may not capture epigenetic modiﬁcations, including
heritable epigenetic traits
Epigenetic modiﬁcations are alterations to genes other than in
their base-pair code that alter how, or whether, they are tran-
scribed. They may be the result of environmental inﬂuences or a
consequence of the activity of other genes. They may be inherited.
However, epigenetic modiﬁcations are not captured by some cur-
rent chip-based GWAS techniques nor sequencing technologies.
Importantly, a high proportion of ﬁne-mapped variants are seen in
promoter regions or where regulatory proteins bind, and epigenetic
variation has been identiﬁed in non-hepatic autoimmunity [90].
One epigenetic mechanism that has been proposed as explain-
ing some of the gender differences in prevalence of PBC is biased X
or Y chromosome inactivation. This process typically involves
silencing by chromosome packaging in heterochromatin and has
been reported as being biased in a number of autoimmune diseases
[91,92]. However, it is notable that to date, no risk genes for hepatic
autoimmunity have been identiﬁed on either the X or Y
chromosome.
In PBC further interest a role for epigenetic mechanisms has
been given further support by two recent studies. First is the
observation that the promoter region of the gene encoding CD40
ligand (CD40L) demonstrates reduced methylation in PBC patients
as compared with controls. This is of particular interest given the
key role CD40-CD40 ligand interactions play in B cells activation
and because this observation correlates with serum IgM [93].
G.J. Webb, G.M. Hirschﬁeld / Journal of Autoimmunity 66 (2016) 25e3936Second, recent reports have demonstrated differential DNA
methylation of the promoter region of the gene CXCR3 in T lym-
phocytes from patients with PBC [94]. Demethylation of CXCR3
correlated with increased protein expression of CXCR3. Function-
ally, CXCR3 is present in many inﬂamed tissues and is associated
with the generation of Th1 type responses and the subsequent
migration of Th1 CD4þ T cells. Neither CXCR3 nor CD40L has yet
been associated with risk for developing PBC.
9. The future of genetic investigation of hepatic
autoimmunity
Future investigation of the genetics of hepatic autoimmunity is
likely to take advantage of the increasing efﬁciency and reducing
cost of ﬁner-resolution SNV chips and sparse or whole genome
sequencing. Such “post-GWAS” strategies are starting to reveal new
risk loci in other conditions [95]. Moves towards higher-resolution
assessment of the genome that stop short of full sequencing may
also yield extra information as suggested by ImmunoChip studies
[96,97] (with their higher resolution coverage of targeted sub-
sections of the genome) and recent work in other autoimmune
conditions [90]. In addition, improved analyses of multiple SNVs
associated with risk loci have improved our ability to identify
speciﬁc risk-causing variants/mutations. Combining such infor-
mation with knowledge of the epigenome of individual cell types
has begun to direct researchers to highlight where individual var-
iants may have particular effects [90]. For example, in PBC candi-
date SNVs are enriched in CD4þ T cells and B cells. Larger cohorts of
patients will be valuable but may prove challenging to recruit and
meta-analysis including smaller new cohorts as they become
available is likely to continue to provide small incremental returns
[98]. In addition, where patient e and importantly control e co-
horts are well phenotyped there is the potential of linking genetic
data to clinical outcomes and disease subtypes. Indeed, recent work
has taken data on HLA haplotype associations from GWAS and
associated them with presentation and outcome in AIH [62]. The
three carefully phenotyped cohort projects known as UK-PBC, UK-
PSC and UK-AIH are examples of current work that may provide
insights in this direction.
Future genetic work will need to proceed hand-in-hand with
closer examination of environmental inﬂuences, epigenetics and
geneeenvironment interactions and will need to consider genomes
other than in Caucasian populations.
10. Conclusion
In each of PBC, PSC and AIH, there is a clear genetic component
to disease risk. Each also has a signiﬁcant environmental input and
it is uncertain as to the relative contribution of genes, environment
and interactions within and between these inﬂuences. Until
recently, although several risk-bearing HLA haplotypes in these
diseases had been identiﬁed, these were insufﬁcient to explain
much disease heritability. GWAS and analogous focused chip-based
studies have now greatly increased our knowledge of a number of
variants associated with risk for PBC and PSC and begun to inform
our knowledge in AIH. These variants have been mapped to a
number of likely candidate genes. Of particular interest are links to
the IL-12-STAT4 pathway in PBC and the CD28-IL2 pathway in PSC.
However, despite the multiple genetic associations described by
genetic studies to date, the observed genetic component to disease
risk in hepatic autoimmunity is far from explained. Possible reasons
for this include relatively small samples sizes, inherent deﬁciencies
in GWAS methodology in detecting rare variants, and the uncertain
extent of environmental and epigenetic inﬂuences. Further, GWAS
does not yet explain a number of key phenotypic features of thesediseases, nor have results yet mapped to deﬁnite clinical insights as
they have in other autoimmune diseases. These problems are likely
to be addressed by larger, sequencing-based or higher-resolution
SNV-based studies alongside investigation of geneeenvironment
interactions. Such efforts are starting to gain leverage in more
common diseases. Finally, it is a great pleasure to contribute this
paper to the special issue devoted to Diego and Giorgina Vergani,
both of whom have excelled in every aspect of clinical medicine,
from patient care to teaching and, of course, research. This paper is
part of this dedicated issue which is a component of the yearly
efforts of the Journal of Autoimmunity to recognize truly
outstanding ﬁgures in autoimmunology. Previous recipients have
included Abul Abbas, Michael Sela, Ruth Arnon, Noel Rose and Ian
Mackay [99,100]. Giorgina and Diego are ﬁtting to include in this
group.
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